GenFleet Therapeutics
GenFleet Therapeutics’ Blockbuster IPO Highlights China’s KRAS Innovation and G12D Ambitions
GenFleet Therapeutics raised HK$1.82B in its HKEX IPO, surging 106% on debut. With GFH925 approved for NSCLC and GFH375 showing strong early ORR in KRAS G12D NSCLC, the company is advancing its pipeline, partnerships, and competitive position in global oncology.